Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00379522

Vasopressin in Traumatic Hemorrhagic Shock Study

A Multicenter, Randomized, Controlled Trial Assessing Arginine Vasopressin Versus Saline Placebo in Refractory Traumatic Hemorrhagic Shock Patients (VITRIS-study)

Sponsor: Volker Wenzel

Conditions Hemorrhagic Shock Hypovolemia Shock

Interventions Saline placebo Vasopressin

Updated 6 times since 2017 Last updated: Nov 4, 2014 Started: Jul 31, 2010 Primary completion: Oct 31, 2014 Completion: Oct 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hemorrhagic Shock and Hypovolemia, this trial is completed. The trial is conducted by Volker Wenzel and has accumulated 6 data snapshots since 2010. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Volker Wenzel

Data source: Medical University Innsbruck

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amstetten, Austria , Dresden, Germany , Graz, Austria , Göttingen, Germany , Innsbruck, Austria , Krems, Austria , Linz, Austria , Mannheim, Germany , Murnau am Staffelsee, Germany , Salzburg, Austria and 4 more locations